Nahla S. Zidan, Al-Shehri Fawziah S, Mohamed Sakran and Mohamed Elbakry, PHD
The Protective Effect of a Novel Coumarinic Derivative on Streptozotocin Induced Diabetic Rats
Diabetes mellitus (DM) affects more than 415 million persons worldwide. It is one of the most important causative factors of mortality in the developing countries. It was established that Streptozotocin (STZ) is a chemical compound that induces diabetic complications in rats. This study aimed to examine the ability of novel coumarine-caffeic acid derivative: Ethyl-3-(3, 4- dihydroxyphenyl) acrylamido--5-methoxy-1-(4- methoxyphenyl)-10-methyl-8-oxo-1, 8-dihydropyrano [3, 2-f] chromene-2-carboxylate (Compound I) to reduce the diabetic complications induced by STZ.Diabetes was induced in the rats by the injection with STZ (65 mg/Kg b.w). Diabetes was confirmed then we allowed 7 days to stabilize blood glucose level in these rats. Compound I (25 and 50 mg/kg b.w daily for 4 weeks) was injected into diabetic rats. The treated diabetic rats with Compound I had significantly reduced the high blood glucose level, Homeostatic index of insulin resistance (HOMA IR), Triglycerides (TG), Total-Cholesterol (TC), Low Density Lipoprotein-Cholesterol (LDL-c), Very Low Density Lipoprotein- Cholesterol (VLDL-c) and atherogenic index. The treatment with Compound I also resulted in the improvement of the insulin and insulin resistance and significantly increased serum High Density Lipoprotein Cholesterol (HDL-c), Reduced Glutathione (GSH), Superoxide Dismutase (SOD), Catalase (CAT) and Glutathione Peroxidase (GPx) as well as decreased TBARS in the liver of diabetic rats. Compound I showed protective effects against hyperglycemia. It decreases the blood glucose level and improves the lipid profile by scavenging of free radicals and reducing the risk of diabetic complications.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu